Moderna Inc. (Nasdaq: MRNA)

https://www.modernatx.com

Twitter: @moderna_tx

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators. Headquartered in Cambridge, Mass., with a European headquarters in Basel, Switzerland, Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the past five years. *

	Start	2018-08-01 renamed
	Group	Moderna (Group)
	Predecessor	Moderna Therapeutics Inc.
	Industry	mRNA-based drug
	Industry 2	mRNA technology
	Person	Bancel, Stéphane (Moderna 2011– CEO before bioMérieux 201010 CEO + Eli Lilly)
	Person 2	Kim, Lorence H. (Moderna 201903 CFO)

	Region	Cambridge, MA
	Country	United States (USA)
	Street	200 Technology Square
	City	02139 Cambridge, MA
	Tel	+1-617-714-6500
		Address record changed: 2020-12-02

Basic data	Employees	E: 501 to 1,000 (2020-02-12)
	Currency	USD
	Annual sales	60,209,000 (revenue, total, consolidated (2019) 2019-12-31)
	Profit	-514,021,000 (2019-12-31)
	Cash	1,103,000,000 (2019-12-31)

		* Document for ï¿½About Sectionï¿½: Moderna, Inc.. (9/16/20). "Press Release: Moderna Announces First Commercial Organization Outside North America in Switzerland". Cambridge, MA.

		Record changed: 2022-05-02